Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low-dose dobutamine stress echocardiography

Mostrar registro simples

dc.contributor.author Paiva, M. G.
dc.contributor.author Petrilli, A. S.
dc.contributor.author Moises, V. A.
dc.contributor.author Macedo, CRD
dc.contributor.author Tanaka, C.
dc.contributor.author Campos, O.
dc.date.accessioned 2016-01-24T12:38:11Z
dc.date.available 2016-01-24T12:38:11Z
dc.date.issued 2005-12-01
dc.identifier http://dx.doi.org/10.1002/pbc.20488
dc.identifier.citation Pediatric Blood & Cancer. Hoboken: Wiley-liss, v. 45, n. 7, p. 902-908, 2005.
dc.identifier.issn 1545-5009
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/28569
dc.description.abstract Aim. To assess the late cardioprotective effect of dexrazoxane associated with doxorubicin during treatment of osteosarcoma by means of low-dose dobutamine stress echocardiography (LDDSE) in non-relapsed asymptomatic children and teenagers.Patients and Methods. the study population included 58 patients with osteosarcoma divided in three groups, with equivalent age range, gender proportion and body surface area. Group I (21 patients, 14 males, 15 +/- 4 years) was analyzed before chemotherapy and considered the control group; Group II (19 patients, 11 males, 19.7 +/- 4 years) was treated with 348.4 +/- 18 mg/m(2) of doxorubicin only and Group III (18 patients, 14 male, 16.8 +/- 5 years) treated with 396.5 +/- 55 mg/m(2) of doxorubicin with dexrazoxane in the ratio 10:1. the patients were submitted to LDDSE (maximal dose 5 mu g/ kg/min). No major side effects were observed. Heart rate, blood pressure, left ventricular diameters, end systolic wall stress (ESWS), and other diastolic and systolic function indexes were assessed at rest conditions and during LDDSE and compared between the three groups.Results. Group III received a doxorubicin dose significantly greater than Group II (P = 0.001). During LDDSE there were no significant changes in the diastolic function indexes in any of the groups, but there was a significant increase of systolic indexes and a decrease of ESWS in Group III compared to group II. There was no significant difference of any systolic functional parameters between Group I and III. Considering the ejection fraction (EF) at rest or at LDDSE, 13 patients (69.4%) in Group II and 5 patients (27.7%) in Group III were considered to have systolic dysfunction. (P = 0.02).Conclusion. Myocardial response to LDDSE in patients treated with doxorubicin and dexrazoxane was similar to patients without chemotherapy and better than those treated with doxorubicin only, suggesting less cardiotoxicity. en
dc.format.extent 902-908
dc.language.iso eng
dc.publisher Wiley-Blackwell
dc.relation.ispartof Pediatric Blood & Cancer
dc.rights Acesso restrito
dc.subject cardiomyopathy en
dc.subject cardiotoxicity after cancer therapy en
dc.subject osteosarcoma en
dc.subject pediatric oncology en
dc.title Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low-dose dobutamine stress echocardiography en
dc.type Artigo
dc.rights.license http://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution GRACC
dc.description.affiliation Universidade Federal de São Paulo, Dept Cardiol, EPM, São Paulo, Brazil
dc.description.affiliation GRACC, Pediat Inst Oncol, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Dept Cardiol, EPM, São Paulo, Brazil
dc.identifier.doi 10.1002/pbc.20488
dc.description.source Web of Science
dc.identifier.wos WOS:000232840200008



Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples